Abstract | PURPOSE: MATERIALS AND METHODS: In all, 153 women with Breast Imaging Reporting and Data System (BI-RADS) 3–5 findings on mammography and/or ultrasound underwent identical breast MRI exams at 1.5T with gadobenate dimeglumine and gadopentetate dimeglumine. Images were evaluated by three independent blinded radiologists. Mammography, ultrasound, and combined mammography and/or ultrasound findings were available for 108, 109, and 131 women. Imaging findings were matched with histology data by a fourth, independent, blinded radiologist. Malignant lesion detection rates and diagnostic performance were compared. RESULTS: In all, 120, 120, and 140 confirmed malignant lesions were present in patients undergoing MRI+mammography, MRI+ultrasound, and MRI+mammography and/or ultrasound, respectively. Significantly greater cancer detection rates were noted by all three readers for comparisons of gadobenate dimeglumine-enhanced MRI with mammography (Δ15.8–17.5%; P < 0.0001), ultrasound (Δ18.3–20.0%; P < 0.0001), and mammography and/or ultrasound (Δ8.6–10.7%; P ≤ 0.0105) but not for comparisons of gadopentetate dimeglumine-enhanced MRI with conventional techniques (P > 0.05). The false-positive detection rates were lower on gadobenate dimeglumine-enhanced MRI than on conventional imaging (4.0–5.5% vs. 11.1% at mammography; 6.3–8.4% vs. 15.5% at ultrasound). Significantly improved cancer detection on MRI was noted in heterogeneously dense breast (91.2–97.3% on gadobenate dimeglumine-enhanced MRI vs. 77.2–84.9% on gadopentetate dimeglumine-enhanced MRI vs. 71.9-84.9% with conventional techniques) and for invasive cancers (93.2–96.2% for invasive ductal carcinoma [IDC] on gadobenate dimeglumine-enhanced MRI vs. 79.7–88.5% on gadopentetate dimeglumine-enhanced MRI vs. 77.0–84.4% with conventional techniques). Overall diagnostic performance for the detection of cancer was superior on gadobenate dimeglumine-enhanced MRI than on conventional imaging or gadopentetate dimeglumine-enhanced MRI. CONCLUSION:
Gadobenate dimeglumine-enhanced MRI significantly improves cancer detection compared to gadopentetate dimeglumine-enhanced MRI, mammography, and ultrasound in a selected group of patients undergoing breast MRI for preoperative staging or because of inconclusive findings at conventional imaging.
|
Authors | Fiona J Gilbert, Harrie C M van den Bosch, Antonella Petrillo, Katja Siegmann, Johannes T Heverhagen, Pietro Panizza, Hans-Björn Gehl, Federica Pediconi, Felix Diekmann, Wei-Jun Peng, Lin Ma, Francesco Sardanelli, Paolo Belli, Stefano Corcione, Christian M Zechmann, Matthieu Faivre-Pierret, Laura Martincich |
Journal | Journal of magnetic resonance imaging : JMRI
(J Magn Reson Imaging)
Vol. 39
Issue 5
Pg. 1272-86
(May 2014)
ISSN: 1522-2586 [Electronic] United States |
PMID | 25006633
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Contrast Media
- Organometallic Compounds
- gadobenic acid
- Meglumine
- Gadolinium DTPA
|
Topics |
- Breast Neoplasms
(diagnosis)
- Contrast Media
- Female
- Gadolinium DTPA
- Humans
- Image Enhancement
(methods)
- Magnetic Resonance Imaging
(methods)
- Meglumine
(analogs & derivatives)
- Middle Aged
- Organometallic Compounds
- Reproducibility of Results
- Sensitivity and Specificity
- Ultrasonography, Mammary
(methods)
|